K. Lamb, S. Lohdi, and H. Meier-kriesche, Long-Term Renal Allograft Survival in the United States: A Critical Reappraisal, American Journal of Transplantation, vol.3, issue.Suppl 2, pp.450-462, 2012.
DOI : 10.1111/j.1600-6143.2010.03283.x

M. Hanaway, E. Woodle, S. Mulgaonkar, V. Peddi, D. Kaufman et al., Alemtuzumab Induction in Renal Transplantation, New England Journal of Medicine, vol.364, issue.20, pp.1909-1919, 2011.
DOI : 10.1056/NEJMoa1009546

H. Meier-kriesche, S. Li, R. Gruessner, J. Fung, R. Bustami et al., Immunosuppression: evolution in practice and trends, Am J Transplant, vol.6, pp.111-131, 1994.
DOI : 10.1111/j.1600-6143.2006.01270.x
URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.494.5295

H. Ekberg, H. Tedesco-silva, A. Demirbas, S. Vítko, B. Nashan et al., Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation, New England Journal of Medicine, vol.357, issue.25, pp.2562-2575, 2007.
DOI : 10.1056/NEJMoa067411

R. Gaston, Chronic Calcineurin Inhibitor Nephrotoxicity: Reflections on an Evolving Paradigm, Clinical Journal of the American Society of Nephrology, vol.4, issue.12, pp.2029-2034, 2009.
DOI : 10.2215/CJN.03820609

J. Sellarès, D. De-freitag, M. Mengel, J. Reeve, G. Einecke et al., Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence, American Journal of Transplantation, vol.10, issue.2, pp.388-399, 2012.
DOI : 10.1111/j.1600-6143.2011.03840.x

L. Wilson, Recent patents in the discovery of small molecule inhibitors of JAK3, Expert Opinion on Therapeutic Patents, vol.11, issue.5, pp.609-623, 2010.
DOI : 10.1126/science.1087061

D. Wojciechowski and F. Vincenti, Targeting JAK3 in kidney transplantation, Current Opinion in Organ Transplantation, vol.16, issue.6, pp.614-619, 2011.
DOI : 10.1097/MOT.0b013e32834c23ce

A. Wilks, A. Harpur, R. Kurban, S. Ralph, G. Zürcher et al., Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase., Molecular and Cellular Biology, vol.11, issue.4, pp.2057-2065, 1991.
DOI : 10.1128/MCB.11.4.2057

R. Buckley, The multiple causes of human SCID, Journal of Clinical Investigation, vol.114, issue.10, pp.1409-1411, 2004.
DOI : 10.1172/JCI200423571

P. Changelian, M. Flanagan, D. Ball, C. Kent, K. Magnuson et al., Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor, Science, vol.302, issue.5646, pp.875-878, 2003.
DOI : 10.1126/science.1087061

O. Shea, J. Pesu, M. Borie, D. Changelian, and P. , A new modality for immunosuppression: targeting the JAK/STAT pathway, Nature Reviews Drug Discovery, vol.162, issue.7, pp.555-564, 2004.
DOI : 10.1016/S0960-894X(00)00051-2

D. Borie, P. Changelian, M. Larson, M. Si, R. Paniagua et al., Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates, Transplantation, vol.79, issue.7, pp.791-801, 2005.
DOI : 10.1097/01.TP.0000157117.30290.6F

R. Paniagua, M. Si, M. Flores, G. Rousvoal, S. Zhang et al., Effects of JAK3 Inhibition with CP-690,550 on Immune Cell Populations and Their Functions in Nonhuman Primate Recipients of Kidney Allografts, Transplantation, vol.80, issue.9, pp.1283-1292, 2005.
DOI : 10.1097/01.tp.0000177643.05739.cd

D. Borie, M. Larson, M. Flores, A. Campbell, G. Rousvoal et al., Combined Use of the JAK3 Inhibitor CP-690,550 with Mycophenolate Mofetil to Prevent Kidney Allograft Rejection in Nonhuman Primates, Transplantation, vol.80, issue.12, pp.1756-1764, 2005.
DOI : 10.1097/01.tp.0000184634.25042.ea

E. Van-gurp, W. Weimar, R. Gaston, D. Brennan, R. Mendez et al., Phase 1 Dose-Escalation Study of CP-690???550 in Stable Renal Allograft Recipients: Preliminary Findings of Safety, Tolerability, Effects on Lymphocyte Subsets and Pharmacokinetics, American Journal of Transplantation, vol.76, issue.Suppl 2, pp.1711-1718, 2008.
DOI : 10.1111/j.1600-6143.2008.02307.x

M. Quaedackers, W. Mol, S. Korevaar, E. Van-gurp, W. Van-ijcken et al., Monitoring of the Immunomodulatory Effect of CP-690,550 by Analysis of the JAK/STAT Pathway in Kidney Transplant Patients, Transplantation, vol.88, issue.8, pp.1002-1009, 2009.
DOI : 10.1097/TP.0b013e3181b9ced7

E. Van-gurp, W. Schoordijk-verschoor, M. Klepper, S. Korevaar, G. Chan et al., The Effect of the JAK Inhibitor CP-690,550 on Peripheral Immune Parameters in Stable Kidney Allograft Patients, Transplantation, vol.87, issue.1, pp.79-86, 2009.
DOI : 10.1097/TP.0b013e31818bbea7

S. Busque, J. Leventhal, D. Brennan, S. Steinberg, G. Klintmalm et al., Kidney Allograft Recipients, American Journal of Transplantation, vol.6, issue.Suppl 2, pp.1936-1920, 2009.
DOI : 10.1111/j.1600-6143.2009.02720.x

V. Sewgobind, M. Quaedackers, L. Van-der-laan, R. Kraaijeveld, S. Korevaar et al., The Jak Inhibitor CP-690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells, American Journal of Transplantation, vol.17, issue.8, pp.1785-1795, 2010.
DOI : 10.1111/j.1600-6143.2010.03200.x

F. Vincenti, H. Tedesco-silva, S. Busque, O. Connell, P. Friedewald et al., Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year, American Journal of Transplantation, vol.7, issue.9, pp.2446-2456, 2012.
DOI : 10.1111/j.1600-6143.2012.04127.x

D. Borie, O. Shea, J. Changelian, and P. , JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants, Trends in Molecular Medicine, vol.10, issue.11, pp.532-541, 2004.
DOI : 10.1016/j.molmed.2004.09.007